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Prognostic significance of bone 
marrow and spleen 18F‑FDG uptake 
in patients with colorectal cancer
Jae‑Hoon Lee1, Hye Sun Lee2, Soyoung Kim1, Eun Jung Park3, Seung Hyuk Baik3, 
Tae Joo Jeon1, Kang Young Lee4, Young Hoon Ryu1 & Jeonghyun Kang3*
Serum inflammatory markers are used in the prognostication of colorectal cancer (CRC); however, the 
corresponding role of positron emission tomography (PET)‑derived inflammatory markers remains 
unclear. This study aimed to investigate the prognostic value of 18F‑fluorodeoxyglucose (FDG) 
uptake in the bone marrow and spleen of patients with CRC and evaluate the relationship between 
FDG uptake estimates in these organs and serum inflammatory markers. In total, 411 patients who 
underwent preoperative FDG PET/computed tomography (CT) within 1 month of surgery were 
enrolled. The mean standardized uptake values of the bone marrow and spleen were normalized to 
the value of the liver, thereby generating bone marrow‑to‑liver uptake ratio (BLR) and spleen‑to‑liver 
uptake ratio (SLR) estimates. The value of BLR and SLR in predicting overall survival (OS) was assessed 
using the Cox proportional hazards model. The correlation between BLR or SLR and neutrophil‑to‑
lymphocyte ratio (NLR) was evaluated. The predictive accuracy of BLR alone and in combination 
with SLR was compared using the integrated area under the receiver operating characteristic curves 
(iAUC). In the univariate analysis, BLR (> 1.06) and SLR (> 0.93) were significant predictors of OS. In the 
multivariate analysis, BLR was an independent predictor of OS (hazard ratio = 5.279; p < 0.001). Both 
BLR and SLR were correlated with NLR (p < 0.001). A combination of BLR and SLR was better than 
BLR alone at CRC prognostication (iAUC, 0.561 vs. 0.542). FDG uptake estimates in the bone marrow 
and spleen may be useful imaging‑derived biomarkers of systemic inflammation, supporting CRC 
prognostication.
Colorectal cancer (CRC) is among the most common causes of death  worldwide1. Although incidence and mor-
tality rates remain high, survival outcomes of patients with CRC have improved owing to advances in surgical 
techniques, advent of improved chemotherapeutic drugs, and refinements in radiation  therapy2. Reliable prog-
nostic biomarkers and accurate pretreatment evaluation tools are also paramount to the management of CRC.
18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely 
used in CRC staging, treatment response assessment, recurrence diagnosis, and  prognostication3. PET/CT is 
mostly used for primary lesion assessments; however, it can also be used to investigate non-oncologic pathologies 
such as infection and  inflammation4. Recent studies have implicated inflammation as a critical part of tumor 
microenvironment in various types of cancer, where it affects tumor development, survival, and response to 
 treatment5. Consequently, systemic inflammatory surrogate markers such as C-reactive protein levels, neutrophil-
to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio have been investigated as candidate predictors of 
CRC  prognosis3,6–8. Meanwhile, clinical studies have reported a positive correlation between FDG uptake in the 
bone marrow (BM) and spleen on PET/CT and the levels of serum inflammatory and immune  markers9–11, sug-
gesting these parameters may be useful in evaluating inflammation and CRC prognostication.
However, the relevance of PET-derived inflammatory markers (i.e., FDG uptake in the BM and spleen) 
remains unclear in patients with CRC; to date, only two studies have reported regarding the prognostic value of 
FDG uptake in the BM and  spleen12,13. Thus, this study aimed to investigate the prognostic value of FDG uptake 
in the BM and spleen in patients with CRC, along with other clinical and pathologic factors, and evaluate the 
relationship between FDG uptake estimates in these organs and serum inflammatory markers.
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Methods
Patients who underwent preoperative PET/CT examinations, followed by curative surgical resection of stage 
I–IV CRC between November 2007 and November 2013 were enrolled in this study. Patients were eligible for 
the present study if they met the following criteria: (1) pathologically confirmed stage I–IV CRC; (2) availability 
of preoperative PET/CT scans; and (3) surgery with curative intent, including resection of distant metastasis. 
Patients were excluded from the present study if they met the following criteria: (1) baseline PET/CT examina-
tions performed more than 1 month before the surgery; (2) diagnosis of hereditary nonpolyposis CRC, ulcera-
tive colitis, or Crohn’s disease; (3) diagnosis of another acute inflammatory disease, or (4) unmeasurable target 
organ or tumor uptake (Supplementary Fig. S1 online). This retrospective single-center study included a total 
of 411 patients.
For preoperative staging assessment, blood cell count and carcinoembryonic antigen (CEA) levels were 
assessed; colonoscopy, chest and abdominopelvic CT, and PET/CT were performed for all enrolled patients. The 
American Society of Anesthesiology (ASA) grade and body mass index (BMI) were recorded. NLR was based 
on the white blood cell count. The median interval between baseline PET/CT and surgical resection was 6 days 
(interquartile range [IQR] 3–10 days). After a preoperative staging workup, all patients underwent curative sur-
gery, including resection of distant metastasis. The T and N histopathologic stages were determined according 
to the 7th American Joint Committee on Cancer (AJCC) staging guidelines. The presence of lymphovascular 
invasion (LVI), microsatellite instability (MSI), and KRAS mutations was evaluated using surgical specimens. 
Methodological details of  MSI14 and  KRAS15 mutation evaluation have been described elsewhere. After curative 
surgery, adjuvant chemotherapy was performed, as suitable, and all patients underwent routine follow-up assess-
ments, including blood tests and conventional chest and abdominopelvic CT, every 3–6 months.
The study protocol adhered to the ethical standards of the institutional and/or national research commit-
tees and 1964 Helsinki Declaration and its later amendments. The institutional review board of the Gangnam 
Severance Hospital, Yonsei University College of Medicine, approved this study and waived the requirement for 
written informed consent owing to the retrospective study design.
Image acquisition and processing. All patients were asked to fast for at least 6 h before undergoing PET/
CT, which was performed when blood glucose levels were < 150 mg/dL. Sixty minutes after intravenously admin-
istering FDG (5.5 MBq/kg of body weight), PET/CT was performed using a hybrid PET/CT scanner (Biograph 
40TruePoint or Biograph mCT 64, Siemens Healthcare Solutions USA, Inc., Knoxville, TN). Low-dose CT data 
were first obtained for attenuation correction using the automatic dose modulation with a reference of 40 mA 
and 120 kV without contrast enhancement. The PET data were then acquired from the skull base to the proxi-
mal thigh for 3 min per bed position in a three-dimensional mode. The PET images were reconstructed using 
the ordered subset expectation maximization with attenuation that involved two iterations and 21 subsets. The 
matrix size and thickness of the reconstructed PET images were 128 × 128 mm and 5 mm, respectively.
Image analysis. PET/CT images were retrospectively assessed by two board-certified nuclear medicine 
physicians who were blinded to patient outcomes. Discrepancies in assessments between the physicians were 
resolved by consensus. First, a volume of interest (VOI) was manually drawn around the primary tumor, taking 
care to avoid physiologic FDG uptake, especially in the urinary bladder and both urinary tracts. The maximum 
standardized uptake value  (SUVmax) of the primary tumor was calculated as follows: (decay-corrected activ-
ity per milliliter of tissue volume)/(injected FDG activity per gram of body mass). Subsequently, FDG uptake 
values in the BM, spleen, and liver were measured. For the BM, the spheroid VOIs were drawn over at least five 
vertebral bodies of the lumbar and lower thoracic spines. Vertebrae with severe compression, osteoporosis, or 
postoperative change were excluded from the measurements. For each VOI, an isocontour set at 75% of  SUVmax 
was automatically generated and the mean value of the voxels within the isocontour was measured and defined 
as the BM SUV. For the spleen SUV, one spherical VOI of size 1.5 cm in diameter was placed at the center of the 
spleen, and the mean SUV was measured. Finally, for liver measurements, a spherical VOI of 2 cm was placed in 
the right lobe of the normal liver, and the mean SUV was then measured. The tumor-to-liver uptake ratio (TLR), 
BM-to-liver uptake ratio (BLR), and spleen-to-liver uptake ratio (SLR) were then calculated by dividing the 
 SUVmax of the primary tumor, BM SUV, and spleen SUV each by the mean SUV of the liver.
Statistical analysis. Patients’ clinicopathologic characteristics were examined using a variance test, where 
appropriate. The chi-square and Fisher exact tests were used to compare categorical variables, as suitable. The 
Student’s t test and Mann–Whitney U test were used to compare continuous variables, as suitable.
The primary outcome was overall survival (OS), defined as the time between the day of imaging acquisition 
and death owing to any cause or the last follow-up date. The Cox proportional hazards regression model was used 
to assess the association between variables of interest and OS in the univariate and multivariate analyses. Variables 
with p values < 0.05 in the univariate analysis were included in the multivariate analyses using backward stepwise 
selection. Patients were dichotomized into “high” and “low” groups based on BLR and SLR estimates using the 
optimal cut-off values determined by the largest Χ2 in the Mantel–Cox  test16. OS curves were compared using 
the Kaplan–Meier method; differences in OS estimates were compared between groups using the log-rank test.
To explore the clinical utility of BLR and SLR as a combined variable, patients were divided into four groups: 
low BLR and low SLR (group 1), low BLR and high SLR (group 2), high BLR and low SLR (group 3), and high 
BLR and high SLR (group 4). Differences in the levels of serum inflammatory markers and OS estimates were 
evaluated among these four groups. Moreover, the accuracy of PET-derived biomarkers in predicting OS was 
compared between BLR alone and in combination with SLR using an integrated time-dependent area under 
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the curve (iAUC). Differences in iAUC estimates between the PET-derived parameters were measured using 
bootstrapping with a resampling number of 1,000.
Continuous variables are reported as medians with an IQR, unless otherwise specified. Spearman’s correla-
tion coefficients were calculated to assess the correlation between two variables. The Mann–Whitney U test and 
Kruskal–Wallis test were used to compare median values among groups. All statistical analyses were conducted 
using GraphPad Prism 8 (GraphPad Software, La Jolla, CA, USA). Statistical significance was set at p values < 0.05.
Results
A total of 411 (247 men) patients with CRC were included in this study (Table 1). On preoperative FDG PET/
CT, the primary colon cancer demonstrated higher FDG uptake than normal liver, with the median TLR of 4.65. 
In contrast, the BM and spleen demonstrated lower overall FDG uptake than the liver, and the median BLR and 
SLR were 0.83 and 0.82, respectively. The median follow-up period was 91.4 (range 2.1–142.6) months. A total 
of 120 (29.2%) patients died during the follow-up period.
Predictors of OS. The prognostic relevance of sex, age, ASA grade, BMI, preoperative CEA level, tumor 
location, tumor size, histologic grade, LVI, number of retrieved lymph nodes (LNs), AJCC stage, MSI, KRAS 
mutation status, NLR, TLR, BLR, and SNR was assessed in the survival analysis. The optimal cut-off values for 
BLR and SLR were determined based on the X-tile program, which yielded 1.06 for BLR and 0.93 for SLR (Sup-
plementary Fig. S2 online). Otherwise, empirical cut-off values were used for the other continuous variables.
In the univariate analyses, age (p < 0.001), ASA grade (p = 0.002), BMI (p = 0.001), CEA (p = 0.001), tumor 
size (p = 0.023), LVI (absent vs. present, p < 0.001), number of retrieved LNs (p = 0.031), AJCC stage (I and II 
vs. IV, p < 0.001), postoperative chemotherapy (p < 0.001), BLR (p < 0.001), and SLR (p = 0.030) were signifi-
cantly associated with OS (Table 2). TLR was not associated with OS (p = 0.965). The Kaplan–Meier method 
revealed that patients with higher BLR (> 1.06) had shorter OS than those with lower BLR (89.6 vs. 114.8 months, 
p = 0.002; Fig. 1A). Similarly, patients with higher SLR (> 0.93) had shorter OS than those with lower SLR (98.4 
vs. 115.3 months, p = 0.008; Fig. 1B).
Among the variables that were significantly associated with OS in the univariate analyses, age, ASA grade, 
BMI, CEA, LVI, number of retrieved LNs, AJCC stage, chemotherapy, BLR, and SLR were included in the mul-
tivariate analysis (Table 2). The multivariate analysis revealed that age (p < 0.001), ASA grade (1 vs. 2, p < 0.001), 
BMI (p = 0.002), LVI (absent vs. present, p = 0.027), number of retrieved LNs (p < 0.001), AJCC stage (I and II vs. 
III, p = 0.002; I and II vs. IV, p < 0.001), chemotherapy (p = 0.002), and BLR (p < 0.001) were independent predic-
tors of OS (Table 2). SLR was not an independent predictor of OS in the multivariate analysis.
Correlation of BLR and SLR with NLR. BLR and SLR correlated positively with NLR (r = 0.27, p < 0.001 
for BLR; Supplementary Fig. S3A online; r = 0.17, p < 0.001 for SLR, Supplementary Fig. S3B online). However, 
TLR was not correlated with NLR (r = 0.08, p = 0.088). The high BLR group demonstrated higher NLR than the 
low BLR group; the median LNRs were 3.16 (IQR, 2.22) and 2.39 (2.22) for the high BLR and low BLR groups, 
respectively (p < 0.001) (Fig. 4A). The high SLR group had higher NLR than the low SLR group; the median 
LNRs were 2.99 (2.69) and 2.38 (1.52) for the high SLR and low SLR groups respectively (p < 0.001) (Fig. 4B).
Additive prognostic value of BLR and SLR. Patients were divided into low BLR and low SLR (group 1, 
n = 309), low BLR and high SLR (group 2, n = 50), high BLR and low SLR (group 3, n = 18), and high BLR and high 
SLR (group 4, n = 34) groups. The univariate analysis demonstrated a significant difference in OS among the four 
groups (p < 0.001). Post-hoc analyses revealed that patients with BLR of > 1.06 and SLR of > 0.93 (group 4) had 
poorer prognosis than those with BLR of ≤ 1.06 and SLR of ≤ 0.93 (group 1) (p < 0.001) (Supplementary Table S1 
online). The Kaplan–Meier method revealed poorer OS in group 4 than in group 1 (83.6 vs. 115.9  months; 
p = 0.001) (Fig. 2). In the multivariate analysis, the four-group variable derived from the combination of BLR 
and SLR was an independent predictor of OS (group 1 vs. group 4, p = 0.007) (Supplementary Table S1 online). 
The iAUC value of the four-group variable (0.562; 95% confidence interval [CI], 0.522–0.601) was superior to 
that of the two-group variable based on BLR (0.542; CI, 0.508–0.578) throughout the observation period, with 
an estimated difference of 0.018 (00.001–0.049) (Fig. 3). NLR was significantly different among the four groups; 
post-hoc analysis revealed that group 1 had significantly lower NLR than the other three groups (Fig. 4C).
Discussion
The present study showed that both BM and spleen uptake of FDG on preoperative PET/CT may be useful 
biomarkers of systemic inflammation associated with CRC prognosis. BLR was independently associated with 
OS in the multivariate analysis. SLR was a significant predictor of OS in the univariate analysis but not in the 
multivariate analysis. Both BLR and SLR were positively correlated with NLR, which is a systemic inflammatory 
marker. Moreover, a combination of BLR and SLR was superior to BLR alone in OS prognostication.
BM is vital for hematopoiesis and neutrophil production, which is regulated by the release of the cytokine 
granulocyte colony-stimulating  factor17. Previous studies have shown that FDG uptake by the BM is increased 
in several types of cancer and that it correlates with the levels of serum cytokines, C-reactive protein, and 
other hematologic parameters, which may be indicative of the BM activation in response to tumor-associated 
 inflammation9–11. Inflammatory markers are present in the tumor microenvironment, and tumors frequently 
develop at the location of chronic  inflammation5. Inflammation is involved in tumor progression, and baseline 
systemic inflammation is associated with poor clinical outcomes in cancer  patients18–20. Consequently, FDG 
uptake by the BM may be relevant to CRC prognostication; because FDG uptake can be determined using PET, 
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which is a non-invasive imaging modality, this parameter can be easily integrated into clinical practice and 
research.
The spleen plays an important role in hematopoiesis and  immunity21; it filters and stores red blood cells, 
belongs to the mononuclear phagocyte system, and produces lymphocytes. Diffusely increased FDG uptake in 
the spleen can be observed in several diseases, including inflammatory and oncological  conditions22. Previous 
studies have evaluated the prognostic significance of diffuse splenic uptake in some  cancers23–25, thus demon-
strating that FDG uptake in the spleen observed on baseline FDG PET/CT may help predict disease recurrence 
or disease-specific mortality, particularly when used along with hematologic or inflammatory parameters; the 
present findings are consistent with those of these previous studies. Similar to FDG uptake in the BM, that in 
the spleen may indicate an increase in glucose metabolism owing to immune system activation, which may 
adversely affect patient outcomes.
In the present study, SLR demonstrated a significant positive correlation with NLR; meanwhile, high SLR was 
associated with poor survival in patients with CRC, although this association was not evident in the multivari-
ate analysis. Nevertheless, the combination of BLR and SLR exhibited enhanced prognostic performance over 
BLR alone (iAUC, 0.561 vs. 0.542), suggesting that it may help identify patients at high risk of death and those 
requiring close monitoring or anti-inflammatory therapy. These findings may be associated with the distinct 
roles of these two organs in hematopoiesis, suggesting that the assessment of FDG uptake in the BM and spleen 
may help predict patient outcomes. However, in the present sub-group analysis, group 3 (n = 18) and group 4 
(n = 34) were both smaller than group 1 (n = 309) and group 2 (n = 50), which may have skewed the presented 
estimates. Further large studies are required to validate the present findings.
In the present study, FDG uptake by the primary CRC was not associated with OS in the univariate analy-
sis (p = 0.965). Some previous studies have demonstrated that  SUVmax of the primary tumor may affect CRC 
 prognosis26,27; other studies have reported that PET/CT parameters are not associated with either disease-free 
survival or  OS28–30. These discrepancies in findings may be because of the variability in tumor SUV measure-
ments, confounded by tumor-associated inflammation. A previous study suggested that higher tumor uptake 
may reflect tumor cell viability and proliferation, contributing to secondary inflammatory  reaction31. However, 
the relationship between tumor and inflammation may differ among patients and tumor types.
To date, only one study with 226 patients with CRC investigated the prognostic value of FDG uptake in the 
BM in predicting recurrence-free survival after curative  resection13. Data on the prognostic significance of FDG 
uptake in the spleen of patients with CRC are also limited; only one study with 161 patients with rectal cancer 
evaluated the role splenic FDG uptake in death prediction after curative  resection12. These studies demonstrated 
that high FDG uptake in the BM and spleen was significantly associated with poor survival, which is concordant 
with the present findings. However, the former study had a short follow-up period (median 32 months), whereas 
the latter study examined only FDG uptake in the spleen of patients with rectal cancer. The present study involved 
a larger population of patients with CRC, demonstrating the potential usefulness of both BM and spleen FDG 
uptake values for reflecting systemic inflammation levels, which may support CRC prognostication.
This study had several limitations. This was a single-center retrospective study that only included patients 
whose post-surgical pathological assessment findings were available and therefore may involve some selection 
bias. Thus, the present findings need to be validated in large multicenter studies. Second, different PET/CT 
scanners were used in this study, which may have resulted in variations in SUV measurements. However, SUV 
was normalized to that of the liver, instead of using absolute values, to reduce the impact of inter-instrumental 
variability. Moreover, relative quantification is practical and convenient for researchers and clinicians alike as one 
can visually evaluate FDG uptake in the tumor and BM relative to that in the liver without using any specialized 
software or equipment. Therefore, FDG uptake values, presented as the SUV ratio relative to that in the liver, is 
a reproducible and generalizable parameter. Nevertheless, further studies are required to elucidate the relation-
ship between the increased SUV of the BM and spleen and systemic inflammation related to tumor cells; such 
studies may involve the measurement of serum cytokine levels and histopathologic analysis of BM aspirates as 
the tumor-infiltrating immune cells.
In conclusion, BLR and SLR were significantly associated with CRC prognosis in the univariate analysis; 
meanwhile, BLR was an independent predictor of OS in the multivariate analysis. Both BLR and SLR dem-
onstrated a significant positive correlation with NLR. Moreover, a combination of BLR and SLR was better in 
predicting OS than BLR alone. Hence, both BLR and SLR examined on preoperative PET/CT can be useful 
image-derived biomarkers of systemic inflammation, thus supporting CRC prognostication.
N (%)
BLR
Median (IQR) 0.83 (0.730–0.955)
SLR
Median (IQR) 0.82 (0.740–0.910)
Table 1.  Patients’ characteristics. ASA American Society of Anesthesiology, BMI body mass index, CEA 
carcinoembryonic antigen, LVI lymphovascular invasion, LN lymph node, MSI microsatellite instability, MSS 
microsatellite Stable, NLR neutrophil-to-lymphocyte ratio, TLR tumor-to-liver ratio, BLR bone marrow-to-
liver ratio, SLR spleen-to-liver ratio, IQR Interquartile range.
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Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Sex
Female Ref
Male 1.12 (0.772–1.625) 0.55
Age (years)
< 70 Ref Ref
≥ 70 2.261 (1.579–3.238) < 0.001 2.623 (1.772–3.882) < 0.001
ASA
1 Ref Ref
2 1.793 (1.225–2.625) 0.002 1.921 (1.280–2.883) 0.001
3  and  4 1.153 (0.597–2.227) 0.671 0.707 (0.352–1.417) 0.328
No data 1.145 (0.157–8.315) 0.893 0.974 (0.126–7.495) 0.980
BMI (kg/m2)
< 25 Ref Ref
≥ 25 0.424 (0.253–0.708) 0.001 0.431 (0.252–0.738) 0.002
Preop-CEA (ng/mL)
< 5 Ref Ref
≥ 5 1.793 (1.251–2.57) 0.001 1.339 (0.910–1.972) 0.138
Tumor location
Rt. colon Ref
Lt. colon 0.927 (0.605–1.421) 0.730
Rectum 0.916 (0.571–1.471) 0.719
Tumor size (cm)
< 5 Ref
≥ 5 1.516 (1.058–2.172) 0.023
Histologic grade
G1 Ref
G2 1.514 (0.788–2.907) 0.213
G3 1.711 (0.621–4.713) 0.299
Etc 1.485 (0.564–3.905) 0.423
LVI
Absent Ref Ref
Present 2.078 (1.429–3.02) < 0.001 1.602 (1.054–2.435) 0.027
No data 1.621 (0.590–4.45) 0.348 1.485 (0.514–4.286) 0.464
Number of retrieved LNs
< 12 Ref Ref
≥ 12 0.628 (0.411–0.960) 0.031 0.407 (0.259–0.639) < 0.001
Stage
I  and  II Ref Ref
III 1.501 (0.983–2.291) 0.059 2.056 (1.286–3.287) 0.002
IV 5.437 (3.401–8.692) < 0.001 5.560 (3.216–9.610) < 0.001
MSI
MSS/MSI-low Ref
MSI-high 0.643 (0.280–1.479) 0.300
No data 0.962 (0.654–1.415) 0.846
KRAS
Wild Ref
Mutant 1.075 (0.565–2.041) 0.826
No data 1.336 (0.861–2.073) 0.196
Chemotherapy
No Ref Ref
Yes 0.523 (0.365–0.750) < 0.001 0.536 (0.357–0.805) 0.002
NLR
< 3 Ref
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Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Continuous 1.002 (0.934–1.073) 0.965
BLR
Continuous 4.638 (1.958–10.99) < 0.001 5.279 (2.337–11.922) < 0.001
SLR
Continuous 2.686 (1.097–6.574) 0.030
Table 2.  Univariate and multivariate analyses associated with the overall survival (n = 411). HR hazard 
ratio, CI confidence interval, ASA American Society of Anesthesiology, BMI body mass index, CEA 
carcinoembryonic antigen, LVI lymphovascular invasion, LN lymph node, MSI microsatellite instability, MSS 
microsatellite Stable, NLR neutrophil-to-lymphocyte ratio, TLR tumor-to-liver ratio, BLR bone marrow-to-
liver ratio, SLR spleen-to-liver ratio.
Figure 1.  Kaplan–Meier curves of overall survival stratified, according to BLR (A) and SLR (B).
Figure 2.  Kaplan–Meier curves of overall survival stratified by the combination of BLR and SLR. Group 1: low 
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Data availability
The datasets analyzed in this study are not publicly available owing to ethical and privacy restrictions; they are 
available from the corresponding author on reasonable request.
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